NovoCure Ltd. (NASDAQ:NVCR) dropped 2.2% on Monday . The stock traded as low as $7.54 and last traded at $7.65, with a volume of 103,074 shares traded. The stock had previously closed at $7.82.

NVCR has been the topic of several research reports. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. JPMorgan Chase & Co. cut their price objective on shares of NovoCure from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, July 29th. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of NovoCure in a research report on Wednesday, July 6th. Deutsche Bank AG cut their price objective on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, July 29th. Finally, Barclays PLC cut their price objective on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $21.43.

The stock’s 50 day moving average price is $9.13 and its 200 day moving average price is $11.73. The company’s market capitalization is $650.17 million.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, July 28th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.11. The firm earned $17.90 million during the quarter, compared to analysts’ expectations of $15.90 million. On average, equities research analysts predict that NovoCure Ltd. will post ($1.74) EPS for the current fiscal year.

In other NovoCure news, Director Gert L. Perlhagen sold 676,576 shares of the firm’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $1.85, for a total value of $1,251,665.60. Following the transaction, the director now owns 676,576 shares in the company, valued at approximately $1,251,665.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael J. Ambrogi sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total value of $244,800.00. Following the completion of the transaction, the chief operating officer now owns 324,084 shares in the company, valued at approximately $3,966,788.16. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.